These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4385733)

  • 41. [Potassium-magnesium-aspartate therapy in operated cancer patients].
    Kronberger L; Fink E
    Med Klin; 1971 Oct; 66(43):1450-6. PubMed ID: 5001554
    [No Abstract]   [Full Text] [Related]  

  • 42. Studies on progressive muscular dystrophy. I. Effects of adenosinetriphosphate and its related compounds on progressive muscular dystrophy.
    Nakahara M
    Arzneimittelforschung; 1965 Jun; 15(6):591-5. PubMed ID: 4223122
    [No Abstract]   [Full Text] [Related]  

  • 43. An approach to treatment trials in muscular dystrophy with particular reference to agents influencing free radical damage.
    Edwards RH; Jones DA; Jackson MJ
    Med Biol; 1984; 62(2):143-7. PubMed ID: 6471933
    [No Abstract]   [Full Text] [Related]  

  • 44. [Heart insufficiency and potassium-magnesium-aspartic acid].
    Becker F
    Landarzt; 1966 Jan; 42(2):77-8. PubMed ID: 5940673
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of acute myocardial infarct and chronic heart failure using potassium-magnesium aspartate].
    Grujic M; Perinovic M
    Med Welt; 1974 Dec; 25(50):2124-6. PubMed ID: 4444510
    [No Abstract]   [Full Text] [Related]  

  • 46. Treatment of muscular dystrophy.
    Fowler WM
    Arch Phys Med Rehabil; 1973 Jun; 54(6):281-3. PubMed ID: 4708009
    [No Abstract]   [Full Text] [Related]  

  • 47. [Duchenne muscular dystrophy. Effects of vitamin E administration on urinary luminescence].
    Pizarro M; Lissi E; Reyes J; Holmgren J
    Rev Med Chil; 1998 Oct; 126(10):1165-72. PubMed ID: 10030087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The effects of potassium-magnesium aspartate on experimental bioelectric disturbances in cerebral activity induced by a "cardiopathogenic diet"].
    Nikolits I; Szám I
    Arzneimittelforschung; 1965 Sep; 15(9):1025-8. PubMed ID: 5898687
    [No Abstract]   [Full Text] [Related]  

  • 49. [Digitalis and electrolytes. Mechanism of action of potassium-magnesium aspartate].
    Gross W; Hagel H; Hein R; Maiwald L
    Fortschr Med; 1973 Nov; 91(32):1281-5. PubMed ID: 4751358
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinical studies on the therapeutic effect of potassium-magnesium aspartate in coronary disease].
    Szulc EJ
    Wiad Lek; 1968 Sep; 21(17):1509-14. PubMed ID: 4882478
    [No Abstract]   [Full Text] [Related]  

  • 51. [On the behavior of some serum enzymatic activities in subjects with progressive muscular dystrophy treated with nucleotide and nucleoside substances. II. Malate dehydrogenase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase activity].
    Canani MB; Rea F; Capasso DA
    Boll Soc Ital Biol Sper; 1965 Aug; 41(16):901-4. PubMed ID: 5880029
    [No Abstract]   [Full Text] [Related]  

  • 52. [Correlation between the results of traditional electromyographic studies and frequency analysis of the EMG and the severity of the clinical manifestations of muscular dystrophy].
    Goffman V; Ul'rikh KP; Miuller V
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(11):1606-8. PubMed ID: 6524177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of transmethylating factors on hyperglycocyaminuria of progressive muscular dystrophy].
    VERDURA G; SVILOKOS N; SERAFINI L
    Minerva Pediatr; 1959 Mar; 11(11):302-3. PubMed ID: 13656828
    [No Abstract]   [Full Text] [Related]  

  • 54. [Allopurinol in progressive muscular dystrophy (author's transl)].
    Castro-Gago M; Jiménez JF; Torres-Colomer M; Fuster M; Paz M; Novo I; Peña J
    An Esp Pediatr; 1980 Oct; 13(10):865-76. PubMed ID: 7469188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Intravenous therapy of ischemic heart diseases by Tromcardin].
    Wölke F
    Ther Ggw; 1969 Nov; 108(11):1586 passim. PubMed ID: 5379784
    [No Abstract]   [Full Text] [Related]  

  • 56. [On the current treatment of progressive muscular dystrophies in children].
    Edel'shteĭn EA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1968; 68(2):173-7. PubMed ID: 4385315
    [No Abstract]   [Full Text] [Related]  

  • 57. [Progressive muscular dystrophy. Results of a therapeutic trial with glucose-insulin infusions].
    Zett W; Goehler I
    Kinderarztl Prax; 1969 Jul; 37(7):312-24. PubMed ID: 5355989
    [No Abstract]   [Full Text] [Related]  

  • 58. [The treatment of progressive muscular dystrophy with nucleosides and nucleotides. Clinical and serologic findings (aldolase and creatinphosphokinase)].
    Ceccarelli A; Leone P; Moretti A
    Clin Pediatr (Bologna); 1967 Sep; 49(9):468-75. PubMed ID: 5608288
    [No Abstract]   [Full Text] [Related]  

  • 59. [Change in the protein and electrolyte metabolism under the effect of anabolic steroids and panangin in patients with myocardial infarct].
    Leshchinskiĭ LA; Trusov VV; Shinkareva IA
    Klin Med (Mosk); 1978 Jan; 56(1):69-74. PubMed ID: 633803
    [No Abstract]   [Full Text] [Related]  

  • 60. [Therapy of disorders of myocardial metabolism with potassium-magnesium aspartate].
    Reichertz PL; Noell G; Hemmati A
    Med Welt; 1967 Sep; 38():2236-43. PubMed ID: 5614953
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.